Stock Events

Stock Events

Genmab 

€46.60
246
-€2.20-4.51%Friday 07:48

Statistics

Day High
46.6
Day Low
46.6
52W High
51
52W Low
20.8
Volume
-
Avg. Volume
-
Mkt Cap
28.65B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 5Expected
Q4 2025
Q1 2026
Q2 2026
Next
0.42
1.7
2.98
4.26
Expected EPS
3.1100819328
Actual EPS
N/A

Financials

25.9%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
3.22BRevenue
833.35MNet Income

Analyst Ratings

$49.47Average Price Target
The highest estimate is ⁦60.70⁩.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
83%
Hold
17%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GE91.MU. It's not an investment recommendation.
Novo Nordisk
55
NOVO-B.CO
Microsoft
53
MSFT
NVIDIA
40
NVDA
Amazon
38
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG is a major player in biotechnology, directly competing with Genmab in the development of monoclonal antibodies and cancer treatments.
AMGEN
AMGN
Mkt Cap251.94B
Amgen Inc. competes in the biotech space, focusing on innovative therapeutics, including those for cancer, which overlaps with Genmab's focus areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals, Inc. is known for its work in monoclonal antibodies, directly competing with Genmab in several therapeutic areas.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences, Inc. operates in the biopharmaceutical field, competing with Genmab in the development of treatments for diseases such as cancer.
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
Bristol-Myers Squibb Company competes with Genmab in the oncology sector, particularly in the development of innovative cancer treatments.
Merck
MRK
Mkt Cap368.89B
Merck & Co., Inc. is a global healthcare company that competes with Genmab in the development of cancer therapies and immunotherapy treatments.
Novartis
NVS
Mkt Cap303.67B
Novartis AG competes with Genmab in the pharmaceutical and biotechnology sectors, particularly in the development of innovative medicines, including cancer treatments.
Pfizer
PFE
Mkt Cap173.95B
Pfizer Inc. is a global pharmaceutical company that competes with Genmab in the development of drugs for various diseases, including cancer.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca PLC is involved in the discovery and development of pharmaceuticals for several diseases, including cancer, making it a competitor to Genmab.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson operates in the pharmaceutical and biotechnology sectors, competing with Genmab in the development of innovative treatments for diseases, including cancer.

About

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Show More
CEO
Jan van de Winkel
Employees
3119
Country
Denmark
ISIN
US3723032062
WKN
000A1WZYB

Listings

MX
MX
GMAB1N.MX
MX
MX
GMABN.MX
STU
DE
GE91.STU
XETRA
DE
GE9.XETRA

0 Comments

Share your thoughts

FAQs

What is Genmab stock price today?▼
The current price of GE91.MU is €46.60 EUR — it has decreased by -4.51% in the past 24 hours. Watch Genmab stock price performance more closely on the chart.
What is Genmab stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Genmab stocks are traded under the ticker GE91.MU.
Is Genmab stock price growing?▼
GE91.MU stock has fallen by -8.63% compared to the previous week, the month change is a +37.87% rise, over the last year Genmab has showed a +86.4% increase.
What is Genmab market cap?▼
Today Genmab has the market capitalization of 28.65B
When is the next Genmab earnings date?▼
Genmab is going to release the next earnings report on February 24, 2027.
What is Genmab revenue for the last year?▼
Genmab revenue for the last year amounts to 3.22B EUR.
What is Genmab net income for the last year?▼
GE91.MU net income for the last year is 833.35M EUR.
How many employees does Genmab have?▼
As of November 7, 2026, the company has 3,119 employees.
In which sector is Genmab located?▼
Genmab operates in the Health & Wellness sector.
When did Genmab complete a stock split?▼
The last stock split for Genmab was on May 1, 2018 with a ratio of 5:1.
Where is Genmab headquartered?▼
Genmab is headquartered in Copenhagen, Denmark.